Le traitement peut améliorer la qualité de vie, mais il ne guérit pas le déficit enzymatique.
Efficacité du traitementQualité de vieDéficit enzymatique
Complications
5
#1
Quelles sont les complications possibles du déficit ?
Les complications incluent des troubles neurologiques graves et des problèmes de développement.
ComplicationsTroubles neurologiquesDéveloppement
#2
Le déficit peut-il entraîner des problèmes psychologiques ?
Oui, des problèmes psychologiques comme l'anxiété et la dépression peuvent survenir.
Problèmes psychologiquesAnxiétéDépression
#3
Y a-t-il des risques de complications à long terme ?
Oui, les patients peuvent développer des complications à long terme affectant leur qualité de vie.
RisquesComplications à long termeQualité de vie
#4
Les complications sont-elles évitables ?
Certaines complications peuvent être gérées, mais elles ne sont pas entièrement évitables.
Gestion des complicationsPréventionÉvitabilité
#5
Comment surveiller les complications ?
Un suivi régulier avec des spécialistes est essentiel pour surveiller et gérer les complications.
SurveillanceSuivi médicalGestion des complications
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour le déficit ?
Les antécédents familiaux de maladies génétiques augmentent le risque de déficit en galactosylceramidase.
Facteurs de risqueAntécédents familiauxMaladies génétiques
#2
Le sexe influence-t-il le risque ?
Le déficit touche également les deux sexes, mais certaines formes peuvent être plus fréquentes chez les hommes.
SexePrévalenceGénétique
#3
L'origine ethnique joue-t-elle un rôle ?
Oui, certaines populations ont un risque plus élevé de déficits enzymatiques en raison de facteurs génétiques.
Origine ethniquePrédisposition génétiqueRisque
#4
Les facteurs environnementaux sont-ils impliqués ?
Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques.
Facteurs environnementauxRisqueGénétique
#5
Les antécédents médicaux influencent-ils le risque ?
Des antécédents médicaux de troubles métaboliques peuvent augmenter le risque de déficit.
Antécédents médicauxTroubles métaboliquesRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Galactosylceramidase : Questions médicales les plus fréquentes",
"headline": "Galactosylceramidase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Galactosylceramidase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-17",
"dateModified": "2025-03-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Galactosylceramidase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Galactosidases",
"url": "https://questionsmedicales.fr/mesh/D005696",
"about": {
"@type": "MedicalCondition",
"name": "Galactosidases",
"code": {
"@type": "MedicalCode",
"code": "D005696",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.277.450.410"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Galactosylceramidase",
"alternateName": "Galactosylceramidase",
"code": {
"@type": "MedicalCode",
"code": "D005698",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Marco Presta",
"url": "https://questionsmedicales.fr/author/Marco%20Presta",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular and Translational Medicine, Unity of Brescia, University of Brescia, Viale Europa 11, 25123 Brescia, Italy; Italian Consortium for Biotechnology (CIB), Unity of Brescia, University of Brescia, Viale Europa 11, 25123 Brescia, Italy. Electronic address: marco.presta@unibs.it."
}
},
{
"@type": "Person",
"name": "Mirella Belleri",
"url": "https://questionsmedicales.fr/author/Mirella%20Belleri",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular and Translational Medicine, University of Brescia, Italy. Electronic address: mirella.belleri@unibs.it."
}
},
{
"@type": "Person",
"name": "Paola Chiodelli",
"url": "https://questionsmedicales.fr/author/Paola%20Chiodelli",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular and Translational Medicine, University of Brescia, Italy."
}
},
{
"@type": "Person",
"name": "Marzia Corli",
"url": "https://questionsmedicales.fr/author/Marzia%20Corli",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular and Translational Medicine, University of Brescia, Italy."
}
},
{
"@type": "Person",
"name": "Jacob Favret",
"url": "https://questionsmedicales.fr/author/Jacob%20Favret",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnical and Clinical Laboratory Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, New York, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37162564",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00417-023-06083-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39014498",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-024-08334-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design and Methodological Issues of Within-Person (Split-Body) Randomized Controlled Trials Evaluating a Topical Treatment: A Systematic Review.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/36990057",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000530149"
}
},
{
"@type": "ScholarlyArticle",
"name": "Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials.",
"datePublished": "2023-02-17",
"url": "https://questionsmedicales.fr/article/36800063",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10103-023-03734-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial.",
"datePublished": "2023-05-05",
"url": "https://questionsmedicales.fr/article/37145134",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00404-023-07055-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrolases",
"item": "https://questionsmedicales.fr/mesh/D006867"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosidases",
"item": "https://questionsmedicales.fr/mesh/D006026"
},
{
"@type": "ListItem",
"position": 6,
"name": "Galactosidases",
"item": "https://questionsmedicales.fr/mesh/D005696"
},
{
"@type": "ListItem",
"position": 7,
"name": "Galactosylceramidase",
"item": "https://questionsmedicales.fr/mesh/D005698"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Galactosylceramidase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Galactosylceramidase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Galactosylceramidase",
"description": "Comment diagnostiquer un déficit en galactosylceramidase ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes peuvent indiquer un déficit ?\nLe diagnostic est-il difficile à établir ?\nY a-t-il des marqueurs biologiques spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D005698?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Galactosylceramidase",
"description": "Quels sont les symptômes principaux d'un déficit en galactosylceramidase ?\nLes symptômes apparaissent-ils dès la naissance ?\nY a-t-il des symptômes spécifiques chez les adultes ?\nLes symptômes sont-ils réversibles ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D005698?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Galactosylceramidase",
"description": "Peut-on prévenir le déficit en galactosylceramidase ?\nLe dépistage prénatal est-il possible ?\nDes conseils génétiques sont-ils recommandés ?\nLes tests de porteurs sont-ils disponibles ?\nY a-t-il des recommandations pour les familles à risque ?",
"url": "https://questionsmedicales.fr/mesh/D005698?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Galactosylceramidase",
"description": "Quel est le traitement principal pour le déficit en galactosylceramidase ?\nY a-t-il des médicaments spécifiques utilisés ?\nLa physiothérapie est-elle recommandée ?\nDes interventions chirurgicales sont-elles nécessaires ?\nLe traitement est-il efficace à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D005698?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Galactosylceramidase",
"description": "Quelles sont les complications possibles du déficit ?\nLe déficit peut-il entraîner des problèmes psychologiques ?\nY a-t-il des risques de complications à long terme ?\nLes complications sont-elles évitables ?\nComment surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D005698?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Galactosylceramidase",
"description": "Quels sont les facteurs de risque pour le déficit ?\nLe sexe influence-t-il le risque ?\nL'origine ethnique joue-t-elle un rôle ?\nLes facteurs environnementaux sont-ils impliqués ?\nLes antécédents médicaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D005698?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un déficit en galactosylceramidase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests enzymatiques et génétiques pour évaluer l'activité de l'enzyme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sanguins et les analyses d'urine sont couramment utilisés pour détecter le déficit."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un déficit ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes neurologiques, digestifs ou cutanés peuvent suggérer un déficit en galactosylceramidase."
}
},
{
"@type": "Question",
"name": "Le diagnostic est-il difficile à établir ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diagnostic peut être complexe en raison de la variabilité des symptômes et des tests."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de galactosylcéramide dans les fluides biologiques peuvent indiquer un déficit."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux d'un déficit en galactosylceramidase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des problèmes de peau et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils dès la naissance ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître à la naissance ou se développer progressivement durant l'enfance."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les adultes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Chez les adultes, des troubles cognitifs et des problèmes de mobilité peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes ne sont généralement pas réversibles, mais un traitement peut aider à les gérer."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps, entraînant des complications neurologiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le déficit en galactosylceramidase ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de méthode de prévention pour ce déficit génétique."
}
},
{
"@type": "Question",
"name": "Le dépistage prénatal est-il possible ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage prénatal peut identifier les porteurs du gène responsable du déficit."
}
},
{
"@type": "Question",
"name": "Des conseils génétiques sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conseils génétiques peuvent aider les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Les tests de porteurs sont-ils disponibles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests de porteurs sont disponibles pour évaluer le risque de déficit chez les descendants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les familles à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les familles à risque devraient consulter un spécialiste pour des conseils et un suivi appropriés."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour le déficit en galactosylceramidase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la thérapie enzymatique de remplacement pour compenser le déficit."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les analogues de la sphingolipide peuvent être utilisés pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "La physiothérapie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la physiothérapie peut aider à améliorer la mobilité et la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Des interventions chirurgicales sont-elles nécessaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interventions chirurgicales peuvent être nécessaires pour traiter certaines complications."
}
},
{
"@type": "Question",
"name": "Le traitement est-il efficace à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut améliorer la qualité de vie, mais il ne guérit pas le déficit enzymatique."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du déficit ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques graves et des problèmes de développement."
}
},
{
"@type": "Question",
"name": "Le déficit peut-il entraîner des problèmes psychologiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes psychologiques comme l'anxiété et la dépression peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent développer des complications à long terme affectant leur qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles évitables ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais elles ne sont pas entièrement évitables."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier avec des spécialistes est essentiel pour surveiller et gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour le déficit ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de maladies génétiques augmentent le risque de déficit en galactosylceramidase."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le déficit touche également les deux sexes, mais certaines formes peuvent être plus fréquentes chez les hommes."
}
},
{
"@type": "Question",
"name": "L'origine ethnique joue-t-elle un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines populations ont un risque plus élevé de déficits enzymatiques en raison de facteurs génétiques."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils impliqués ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents médicaux de troubles métaboliques peuvent augmenter le risque de déficit."
}
}
]
}
]
}
Department of Molecular and Translational Medicine, Unity of Brescia, University of Brescia, Viale Europa 11, 25123 Brescia, Italy; Italian Consortium for Biotechnology (CIB), Unity of Brescia, University of Brescia, Viale Europa 11, 25123 Brescia, Italy. Electronic address: marco.presta@unibs.it.
Department of Biotechnical and Clinical Laboratory Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, New York, United States of America.
Institute for Myelin and Glia Exploration, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, New York, United States of America.
Department of Biotechnical and Clinical Laboratory Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, New York, United States of America.
Cellular Neuroscience, Neurodegeneration, Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.
Cellular Neuroscience, Neurodegeneration, Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.
Cellular Neuroscience, Neurodegeneration, Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.
Institute for Myelin and Glia Exploration, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, New York, United States of America.
Institute for Myelin and Glia Exploration, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, New York, United States of America.
Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, New York, United States of America.
Diquafosol enhances fluid transfer and mucin secretion on ocular surface, which has been suggested as an effective treatment for dry eye disease (DED). The aim of the systematic review and meta-analys...
Relevant randomized controlled trials were obtained via search of electronic including PubMed, Embase, Cochrane Library, and Web of Science. A random-effects model was used to pool the results after i...
A total of nine RCTs involving 1295 patients with DED were included in the meta-analysis. Compared to treatment with 0.1% HA, topical treatment with 3% diquafosol significantly improved the Ocular Sur...
Topical treatment with 3% diquafosol may be more effective than 0.1% HA for patients with DED. However, the long-term efficacy and tolerability of diquafosol still need to be determined....
Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, a...
A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eli...
The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the prot...
ClinicalTrials.gov NCT05704205. Registered on December 8, 2022....
Topical drugs are often used as first-line treatment for dermatological conditions. A within-person design may then be well adapted: it consists of randomizing lesions/body sites rather than patients,...
The aim of this review was to provide a methodological overview of within-person randomized trials (WP-RCTs) in dermatology....
We searched for eligible trials published between 2017 and 2021 in MEDLINE, Embase, and Central in dermatology journals and the 6 highest-impact-factor general medical journals. Two authors selected p...
From 1,034 articles identified, we included 54 WP-RCTs, mainly for acne vulgaris, psoriasis, actinic keratosis, and atopic dermatitis. In most of the trials, patients had only 2 lesions/body sites. In...
Our systematic review highlights that despite the publication of the CONSORT checklist extension for WP-RCTs in 2017, this design is rarely used, and when it is, there are methodological and reporting...
We aim to evaluate the clinical efficacy and safety of using laser and light combined with topical minoxidil for alopecia areata. We searched PubMed, Embase, Web of Science, the Cochrane Library, Chin...
Vulvar lichen sclerosus (LS) is a chronic debilitating inflammatory skin disease. Today, the gold standard is a life-long topical steroid treatment. Alternative options are highly desired. We present ...
We recruited 66 patients, 44 in the laser arm and 22 in the steroid arm. Patients with a physician-administered clinical LS score ≥ 4 were included. Participants received either four laser treatments ...
The findings of this trial have the potential to offer a novel treatment option for LS. The standardized Nd:YAG/Er:YAG laser settings and the treatment regime are presented in this paper....
NCT03926299....
Alopecia areata (AA) is a common autoimmune skin disease. Our study aimed to systematically evaluate the efficacy and safety of compound glycyrrhizin (CG) combined with topical minoxidil therapy in tr...
We searched the PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP databases. Randomized controlled trials (RCTs) on CG combined with topical minoxidil therapy compared with topi...
11 RCTs and 1189 patients were included. Compared with topical minoxidil therapy alone, CG combined with topical minoxidil therapy was more effective at improving the clinical efficacy (RR = 1.36, 95%...
The current evidence indicates that CG combined with topical minoxidil therapy is effective and safe for AA. However, owing to the suboptimal quality of the included studies, more high-quality and lar...
The purpose was to identify and summarize the existing evidence on the efficacy and safety of the topical application of olive oil for preventing pressure ulcers (PUs). We included only randomized con...
To investigate the clinical efficacy and safety of topical difamilast in mild-to-moderate atopic dermatitis (AD)....
Only randomized controlled trials (RCTs) that compared topical difamilast with vehicle treatment for patients with AD were included. PubMed, Web of Science, Ovid Medline, Cochrane Library, ClinicalTri...
Five studies enrolling a total of 1009 patients with mild-to-moderate AD were identified. Compared with the topical vehicle, topical difamilast was associated with a significantly higher success rate ...
This meta-analysis suggests that topical difamilast is an effective and safe treatment for mild-to-moderate AD....
Melasma is a chronic relapsing skin condition. Laser therapy is a new advancement in treatment. Whether the topical application of tranexamic acid (TXA) increases the efficacy of laser therapy in mela...
Randomized controlled trials are used to estimate the causal effect of a treatment on a health outcome of interest in a patient population. Often the specified treatment in a randomized controlled tri...
We use causal reasoning to explain why randomized controlled trials of biomarker targets can arrive at conflicting or misleading conclusions. We describe four key threats to the validity of trials of ...
We illustrate these findings using evidence from 15 randomized controlled trials of blood pressure targets for management of hypertension. Randomized trials of blood pressure targets exhibit substanti...
Researchers should critically assess meta-analyses of trials of targets for variation in the types, distributions, and off-target effects of therapies studied. Trial investigators should release detai...
